BCVA Improvement in Black Patients with Lucentis for DME

Here’s⁣ a breakdown of the provided text,summarizing the key data:

Main Point:

A ​study examined the impact of race on outcomes of ranibizumab treatment ​for diabetic macular edema. While Black participants initially had better vision, they gained⁢ fewer letters of visual acuity ⁤over two years compared to white​ participants.However, after adjusting for baseline ⁤factors, the outcomes were similar, suggesting the medication itself works​ equally ‍well across races when⁢ access to care is equal. Disparities in outcomes are⁤ likely due to social determinants​ of health.

Key Findings & Insights:

* Ranibizumab Effectiveness: ​The ​study reinforces the⁢ effectiveness ⁢of ranibizumab for ‌diabetic macular ⁢edema.
* ⁣ ‍ Race & Outcomes: Initial differences in visual acuity gain between Black and white ‌patients were ⁢likely due to systemic ⁤factors (access to care, diabetes control, socioeconomic status) rather than​ a biological difference in response to the medication.
*​ Social Determinants of ​Health: The study highlights the ​importance of addressing broader social factors that contribute ‍to health disparities.
* ⁤ Need for ‌Diversity in ‍Trials: The study acknowledges its limitation – a lack ​of diversity, focusing only ‌on Black and white patients. There’s a call for more inclusive clinical trials that reflect the populations served by eye care providers.

Source⁢ & Author:

* ‍ Author: Alek Karthikeyan, OD, ⁢FAAO (Rochester ‌Regional Health, New York)
* Affiliation: American Academy of Optometry Communications​ Committee
* ⁢ Disclosure: Karthikeyan reports no relevant⁤ financial disclosures.
* ⁣ ⁤ Published‍ by: ⁢Primary Care‍ Optometry News (via ‌Healio)

Additional Information:

* Healio AI Promotion: the text includes a​ promotional section for Healio AI, a tool that provides access to clinical information‌ from sources like PubMed, guidelines, and⁣ healio’s news coverage.